Surgical and survival outcomes of sleeve lobectomy after neoadjuvant theraphy in lung cancer: With group of 265 patients

Aim: This study aimed to evaluate surgical and 5-year survival outcomes in patients undergoing sleeve lobectomy and bilobectomy after induction theraphy in treatment of lung cancer. Methods: Our single-centered study included 265 lung cancer patients who were performed sleeve lobectomy and bilobectomy between 2005 and 2020. Patients were divided into two groups who received neoadjuvant therapy and those who did not. All variables affecting overall survival were investigated retrospectively. Results: Of all 265 patients (245 male and 20 female), the mean age was 58.9 years (range: 19-78). Lobectomy was performed to 91.7%, and in 3% of all cases, video-assisted thoracoscopy was preferred. 81.9% of the tumors confirmed to be squamous cell subtype. In the 55 of patients (20,8%) who reiceved neoadjuvant theraphy, R0 resection was provided in all, however according to pathology reports, %3,3 of the patients who did not recieved neoadjuvant theraphy had incomplete resection. The 5-year survival rate was found to be 58.3%, and the median survival time was 80.1 months in all patients, patients with induction theraphy was %56,6 and %58,8 in patient without respectively. There was no significant diffirence statistically. In the cox-regression analysis, patient age, tumor size, lymph node metastasis and histology were determined as variables that affect survival (p Conclusions: In this study, we evaluate surgical outcomes of sleeve lobectomies after neoadjuvant theraphy retrospectively with these large number of patients. And we found that neoadjuvant therapy is not a significant factor for survival in sleeve resections.